The company's breast tomosynthesis cancer detection package analyzes each image, identifying potential areas of interest in the dataset and blending those areas of interest onto a synthetic 2D image, iCAD said. It is available with the company's PowerLook advanced mammography platform.
iCAD expects the technology to receive the CE Mark this month. It anticipates clearance from the U.S. Food and Drug Administration (FDA) later in the year.
Copyright © 2016 AuntMinnie.com